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Background: Patients with metastases in the lymph nodes of the neck and no obvious
primary tumor, neck cancer with unknown primary (NCUP), represent a management
challenge. A majority of patients have metastatic squamous cell carcinoma (SCC),
although other histologies do occur.
Methods: We comprehensively reviewed the literature, compared available guidelines,
and conferred with an international team of experts.
Results: Positron emission tomography-computed tomography (PET-CT) and fine
needle aspiration (FNA) under ultrasound guidance increase accuracy of diagnosis.
Immunohistochemistry (IHC), determination of human papilloma virus (HPV) status, byNovember 2020 | Volume 10 | Article 5931641
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Frontiers in Oncology | www.frontiersin.orgp16 staining or by in situ hybridization (ISH), and next-generation gene sequencing can
guide us regarding probable primary sites and tumor biology. Narrow Band Imaging (NBI)
has been introduced for the early detection of subtle mucosal lesions. Direct laryngoscopy
(DL) and tonsillectomy have long been procedures used in the search for a primary site.
More recently, TransOral Robotic Surgery (TORS) or Transoral LASERMicrosurgery (TLM)
have been introduced for lingual tonsillectomy.
Conclusions: New technologies have been developed which can better detect,
diagnose, and treat occult primary tumors. Decisions regarding therapy are based on
the primary tumor site (if discovered) and N stage. Options include neck dissection with or
without postoperative adjuvant therapy, primary irradiation, or combined chemotherapy
with irradiation. The preferred treatment of patients whose primary remains unidentified is
controversial.Keywords: cervical adenopathy with unknown primary, HPV related head and neck cancer, non-HPV related head
and neck cancer, molecular diagnoses occult primary, upper aerodigestive tract cancers, imaging head and neck
cancer, transoral robotic surgery (TORS), transoral laser microlaryngoscopy (TLM)INTRODUCTION
The patient with proven or suspected metastatic cancer in the
cervical nodes and no evident primary cancer represents a
unique challenge. The majority of these patients will have an
occult squamous cell carcinoma of the upper aerodigestive tract,
although infrequently other histological types and primary sites
do occur. Identification of the primary site allows us to direct
appropriate treatment strategies. This topic was well-reviewed by
Strojan et al. (1, 2) in a two-part series in 2013. Our goal is to
update the reader regarding the various innovations that have
occurred in a time of increased incidence of HPV-related head
and neck cancer.DEFINITION OF METASTATIC NECK
CARCINOMA IN THE NECK WITH
UNKNOWN PRIMARY
Many patients with cervical lymphatic metastases start out as
“unknown primaries”, but most have primaries identified on
careful physical examination, office endoscopy, and imaging (3).
Only after such an evaluation can patients be categorized as neck
cancer with an unknown primary (NCUP). We introduce more
specific abbreviation NCUP rather than CUP, which is also
commonly used for widespread systemic cancer metastases
below the clavicles with unknown primary.
NCUP occurs in 1 to 7% of new head and neck cancer cases,
and that percentage declines with the extensiveness of the search
for a primary (4). After extensive endoscopic evaluation under
general anesthesia, the percentage of unknown primary tumors
decreases to less than 3%, (5, 6). Some have suggested that the
incidence of patients with NCUP is increasing with the
increasing numbers of HPV-related oropharyngeal cancers
(OPCs) (7).2
Metastatic lymph nodes in the parotid typically result from a
cutaneous primary cancer and this represents a different
discussion. We are focusing on patients who present with
suspicious lymph nodes in levels I, II, III, and VA in the neck
as described in the American Academy of Otolaryngology-Head
and Neck Surgery (AAO-HNS) guidelines regarding
standardized neck anatomic terminology (8). Squamous cell
carcinoma metastases to lymph nodes in these anatomic levels
can develop from skin cancer but are much more often from
an upper aerodigestive tract primary. Other common histologies
in the neck include well-differentiated thyroid malignancies,
and nonsquamous malignancies originating in the skin,
including melanoma, and Merkel cell carcinoma (high-grade
neuroendocrine carcinoma), as well as salivary gland cancers (9).
Isolated supraclavicular nodes (level IV and VB), on the other
hand, are either of thyroid origin or metastatic from primary
sites below the clavicles, the classic “Virchow’s” node, which
include gastrointestinal tract, urogenital tract, esophagus, biliary,
liver, pancreas, lung, breast, and gynecological cancers (9–13).
Even rarer malignant neck masses include soft tissue sarcomas
and cervical metastases from central nervous system tumors
(14, 15).EVALUATION BY THE GENERAL
PRACTITIONER
Hayes Martin stated that “an adult patient who presents with a
palpable lateral neck mass, whether solid or cystic, should be
considered to have a metastatic lymph node until proven
otherwise” (16, 17).
In the typical patient with NCUP, the lymph nodes, located in
the upper part of the neck, are clearly abnormal in size, shape or
consistency. The palpable mass may be firm or, if cystic, may
have a tense or soft consistency. On careful questioning, theNovember 2020 | Volume 10 | Article 593164
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tumor, such as a sore throat when swallowing, ear pain, new
nasal obstruction, voice change, etc. They also may have a history
of tobacco and alcohol abuse or 10 or more lifetime sexual
partners. The absence of suspicious history or symptoms does
not, however, rule out cancer.
If a patient has a clinical presentation and imaging typical of
lymphoma, with widespread adenopathy, sometimes exhibiting
splenic, liver, bone marrow or lung involvement, and sometimes
with “type B” constitutional symptoms (fever, weight loss and
night sweats), this represents an appropriate clinical scenario for
open cervical lymph node biopsy (18, 19). If not, it would be
preferable to presume carcinoma initially and avoid open or even
core biopsy as an initial test.
Since the 1940’s, the inappropriateness of premature
excisional lymph node biopsy for patients with lateral neck
masses has been well recognized (1, 20). The open biopsy itself
does not make neck dissection necessary if chemoradiation is
otherwise the standard treatment based on the primary tumor
ultimately identified (21).
General physicians should have a strong understanding of
the relationship of neck adenopathy to primary tumors of the
upper aerodigestive tract, and a low threshold for referral to a
head and neck specialist (22–24). Computed tomography (CT)
of the neck with iodinated contrast or magnetic resonance
imaging (MRI) with and without gadolinium contrast can be
obtained while awaiting appointment with a head and
neck specialist.Frontiers in Oncology | www.frontiersin.org 3Ultrasound-guided FNA of the neck mass for cytology is also
appropriate prior to referral, but core needle biopsy should be
deferred until after evaluation by the specialist and complete
head and neck physical examination including fiberoptic
nasopharyngo-laryngoscopy (25).THE SPECIALIZED HEAD AND NECK
EVALUATION
Clinical Evaluation
Pertinent patient history and risk factors should be identified,
followed by palpation of the neck, and meticulous physical
examination of the upper aerodigestive tract including
fiberoptic nasopharyngoscopy and laryngoscopy, palpation of
the base of the tongue and tonsils, salivary glands and thyroid,
inspection of the skin and evaluation of cranial nerve function. If
a primary site is suspected, either office biopsy, or direct
laryngoscopy and biopsy under general anesthesia should be
scheduled. After this initial evaluation, imaging, if not already
performed is requested (Figure 1). An ultrasound guided FNA of
the neck mass is now obtained, if not already performed (9).
Imaging
Ultrasound
Diagnostic ultrasound distinguishes solid from cystic masses,
and provides details regarding intranodal anatomy andFIGURE 1 | Evaluation of the adult patient presenting with pathological cervical adenopathy. H&N, Head and Neck; NBI, Narrow Band Imaging; CT, Computed
Tomography; MRI, Magnetic Resonance Imaging; FNA, Fine Needle Aspiration; HPV, Human Papilloma Virus; IHC, Immunohistochemistry; PET-CT, Positron
Emission Tomography-Computed Tomography.November 2020 | Volume 10 | Article 593164
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carcinoma, in thyroid cancer it has a primary role in
evaluating both thyroid nodules and lateral neck lymph nodes
and in detecting pathological features in nodules and nodes that
are not enlarged (26).
Cross-Sectional Imaging
CT with iodinated contrast or MRI of the neck extending from
the skull base to the thoracic inlet is required. CT with contrast is
typically the first test ordered. However, for patients with iodine
allergy MRI with and without gadolinium will represent a
reasonable alternative, and for patients with renal failure, non-
contrasted MRI is the best option (25).
CT or MRI can delineate the anatomy of the cervical
adenopathy, including the relationship of the abnormal nodes
to vascular and visceral structures, and the presence of
additional non-palpable but suspicious nodes, including
possible adenopathy of parapharyngeal, retropharyngeal,
paratracheal, and mediastinal areas. The presence of additional
hidden nodes might point to a primary site. For example,
retropharyngeal nodes would suggest a nasopharyngeal
primary. Paratracheal adenopathy might suggest a thyroid or
esophageal primary site. The imaging study may also directly
image primary sites in the upper aerodigestive tract, detecting
asymmetries of the mucosal surfaces toward which the specialist
can direct their physical examination (25).
Metabolic Imaging: Positron Emission Tomography-
Computed Tomography (PET-CT)
A significant development over the last 10 years has been the
adoption of PET-CT as part of the initial imaging evaluation
specifically for NCUP. Multiple publications suggest that PET-CT,
while prone to false positives and limited accuracy overall, will
direct the head and neck surgeon to a potential primary site in
situations where other imaging modalities have failed (27–29).
However, it is also well established that direct laryngoscopy under
general anesthesia, particularly with the addition of tonsillectomy,
will identify primary tumors in a significant percentage of patients
with negative PET-CT (30). Sokoya et al. (30), in a 10-year
retrospective study of 190 patients, reported that PET-CT had a
sensitivity and negative predictive value (NPV) in detecting the
primary site in unknown primary head and neck squamous cell
carcinoma of 73.1% and 68.9%, respectively. Out of 103 patients
whose PET-CT scans were negative for a primary tumor, 32 had
primary tumors identified on direct laryngoscopy. Tonsillar cancer
represented 56% of the primary tumors identified, 25% were in the
base of tongue, 3% in the nasopharynx, and 3% in the
hypopharynx. Multiple authors support the utility of PET-CT
for NCUP as a guide prior to direct laryngoscopy, despite its
limitations (27–30). In the meta-analysis by Zhu et al, PET-CT
prior to endoscopy under general anesthesia allowed diagnosis of
the primary site in 44% of cases with a sensitivity of 97% and a
specificity of 68% (31). These results should be interpreted with
caution, as the potential for detecting primary lesions through
PET-CT largely depends on the extent and quality of the other
diagnostic procedures performed.Frontiers in Oncology | www.frontiersin.org 4THE ROLE OF FINE NEEDLE ASPIRATION
BIOPSY, CORE BIOPSY, AND OPEN
BIOPSY
If a primary site is not identified on clinical examination, the next
step will be FNA of the neck mass for cytological examination,
preferably under ultrasound guidance (see Figure 1 for workup
of the suspicious neck mass). For patients with solid masses that
harbor squamous cell carcinoma, FNA will be positive in 80% or
more (32–34) and repeated FNA can yield an additional
increment. With cystic neck masses the percentage is lower,
but still, if ultrasound assisted and directed toward the most solid
parts of the lesion, in the majority of patients with a suspicious
neck mass, the FNA will correctly diagnose malignancy
if present.
In those cases which are not squamous cell carcinomas,
and in particular when a primary below the clavicles is
suspected, sophisticated diagnostic approaches, including
immunocytochemistry or immunohistochemistry(IHC) and
molecular techniques are available to help direct a search for a
primary site, based on the biopsy, and this is covered in more
detail later.
With NCUP, the question of when to do an open biopsy of
the neck mass becomes extremely important, since we have no
guarantee that the primary will be located during the work up.
FNA for cytology has a low but significant false negative rate,
particularly for cystic lesions. False positives are much less
common. Tandon et al. performed a review of 30 studies and
then presented 2,702 aspirates from their own institution (35).
Results were consistent for both parts of the study, and at their
institution they reported sensitivity, specificity, positive
predictive value (PPV), NPV, and accuracy rates of 89.5%,
98.5%, 97.3%, 94.0%, and 95.1%, respectively (35). These
statistics are based on the precision of the diagnosis as given.
For example, for thyroid nodules, a diagnosis of a follicular lesion
would be considered positive and correct if it later proved to be a
papillary cancer with follicular areas. A poorly differentiated
malignancy might not be further classified on cytology. However,
for squamous cell carcinomas the diagnosis was made exactly
with a sensitivity of 92% (35).
It is therefore reasonable to start with FNA, since it is less
likely to interfere with future surgery should that be the
treatment of choice. Fine needles have also historically been
favored as the initial procedure over cores, as traditional core
biopsy instruments have ranged from 14 to 18 gauge in diameter,
do not involve automatic suction devices, are performed from
multiple directions, and can be quite traumatic. However FNA
cytology is a triturated sample without tissue architecture, and a
negative cytology of a suspicious mass is simply a failure to
obtain diagnostic cells, and should not be considered
benign (35).
The possibility of applying additional cytopathological and
molecular techniques to the cytologic aspirate, to provide an
estimate regarding the risk of malignancy relative to a benign
branchial cleft cyst, is an area that is open for further study. If a
few non-diagnostic cells are encountered, IHC or in-situNovember 2020 | Volume 10 | Article 593164
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(39) P53 mutations (40), cytokeratin and other markers (41) can
be performed, depending on the viral prevalence in the region
and level of suspicion.
Thyroglobulin levels can be checked on fluid aspirated if
thyroid malignancy is suspected. In a more unique approach,
Nordemar et al. found that the presence of aneuploidy on DNA
analysis predicted malignancy in 53% of malignant aspirates, and
was never present in benign branchial cleft cysts (42). With
further study, this and other sophisticated analyses of the fine
needle aspirate could prove useful in providing an earlier
diagnosis of malignancy.
HPV testing of initial cytology is important in the modern
era, not only to help prove malignancy when material is scant,
but also because of the importance of HPV status as a prognostic
indicator and its potential for de-escalating the treatment
approach. Although most patients will ultimately have
histopathological tissue, either from a core, a primary site
biopsy, or a neck dissection, early information regarding HPV
status can direct the physicians toward the appropriate primary
site and help them begin planning therapy. Daneshpajouhnejad
et al. (43) used HPV-RNA ISH/P16 for HPV testing, a relatively
new technique, and found a concordance rate of 88.9% between
cytology and subsequent histopathology. HPV RNA significantly
improved the accuracy of HPV testing of cytology specimens
over P16 testing alone, which is sensitive but not very specific, as
well as over the use of HPV-DNA ISH, which in previous
publication was found to be technically challenging and less
reliable (44).
Despite our ability to do more sophisticated testing, a non-
diagnostic FNA can still occur. This can be due to low cellularity
of the fluid within a cystic metastasis, the sampling of an area of
necrosis, the sampling of peritumoral inflammation, excessive
vascularity resulting in a bloody specimen, and other possible
reasons (32). For cystic lesions, repeat FNA of a more solid
component could be considered under ultrasound guidance (45).
However, if the tumor is very vascular or very cystic or other
technical issues exist that make repeating the aspiration futile,
the head and neck surgeon may decide to proceed with a more
invasive formal core biopsy procedure.
In order to improve the adequacy of FNA specimens, Allison
et al. (46) recommended adding, at the time of the initial FNA, a
single “small core” with a 20 gauge aspiration core device, as
something close to a fine needle aspiration in terms of tissue
trauma, but providing increased diagnostic yield, including more
accurate IHC and ISH. Using this approach they demonstrated
100% accuracy of HPV IHC and in-situ hybridization (ISH)
on the initial biopsy when surgical follow-up specimens
were available.
Tabet et al. (32) specifically reviewed the management of cystic
metastases with an unknown primary. In 135 cystic metastases of
the neck, they found a high PPV of 92%, but sensitivity of only
59%. They discussed the role of ultrasound-guided core biopsy, in
order to achieve a cancer diagnosis preoperatively, and
confirmatory intraoperative frozen section at the time of open
excisional biopsy performed as a first step with a plan forFrontiers in Oncology | www.frontiersin.org 5completion neck dissection if frozen section confirms positivity.
Ultimately, 72% of their cystic neck masses in adults were proven
malignant, despite presenting with clinical features common to
branchial cleft cysts. Of these, 7.4% were papillary thyroid cancers,
and 62% were squamous cell carcinomas. Among the squamous
cell carcinomas, 17.8% had unknown primary tumors, a higher
percentage than for solid metastases (32).
They recommended selective inclusion of formal core biopsies
in the algorithm for lateral neck masses, particularly if cystic.
This represents a change from the traditional approach, and has
been adopted as a second line option by guidelines in both
Europe and North America (9, 25, 47). For patients in whom
lymphoma is highly suspected; core, incisional, or excisional
biopsy, may be recommended as first step.
When fine needle aspiration fails to produce a diagnosis and
cancer is strongly suspected, obtaining a positive core biopsy may
provide the cancer diagnosis early, making it practically easier to
justify the expense of a PET-CT before panendoscopy. This
approach is supported by several large series showing that the
incidence of clinically significant hematoma, infection, or
seeding of the soft tissues with cancer from core biopsy is low
(35–39, 48–58). At this point, National Cancer Center Network
(NCCN) guidelines in the United States leave core biopsy as an
option to confirm cancer before taking the patient to the
operating room. If possible, the procedure should try to limit
the number of directions from which core biopsies are obtained.
Recently available, self-aspirating powered needles may reduce
the already-low risk of tumor seeding, as tissue is extracted from
a port without removal of the needle, allowing for multiple
biopsies with a single pass. In addition, powered aspiration
may reduce the presence of tumor fragments that could be
dragged out at the time of needle removal (59).
Tabet et al. (32). found the sensitivity of core needle biopsy in
cystic squamous cell carcinoma lymphatic metastases to be 87%.
Frozen section at the time of excision had a 100% sensitivity for
squamous cell carcinoma, though not for other types of
malignancy. Given that core biopsy still results in 13% false
negatives for cystic lesions, some patients will still need open
biopsy to achieve the cancer diagnosis.
An argument in favor of core biopsy prior to endoscopy,
particularly if the FNA cytology is completely non-diagnostic, is
to detect diagnoses other than squamous cell carcinoma prior to
going to the operating room, to avoid the rare, inadvertent
misdiagnosis at frozen section leading to misguided treatment
(56, 59).
For patients in whom a primary has not been located at
panendoscopy, and for whom non-surgical therapy is planned,
we would strongly encourage a core biopsy to achieve an accurate
histological diagnosis, rather than embarking on a course of
chemotherapy and radiation based entirely on cytology. An
exception may be made if PCR for HPV or EBV is positive on
cytology, and the cytology appears unequivocal. However, it is
easy to be fooled, and when the histopathology is not available,
we do not know if an infrequent finding is present that can
confound cytology. The “gold standard” is to enter radiation or
chemoradiation treatment based on histology rather thanNovember 2020 | Volume 10 | Article 593164
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might fall under the cytologic umbrella of “squamous cell
carcinoma” (i.e. nasopharyngeal-type or “lymphoepithelioma”,
basaloid, spindle cell, papillary, undifferentiated, adenoid
squamous, etc.), but have specific clinical features that make a
difference, as well as related pathologies (i.e. mucoepidermoid
carcinoma) that can be misread as squamous cell carcinoma on
cytology. More IHC and molecular tests generally are more
accurate in histopathologic specimens (32). Excisional biopsy
of a mass or node, without completion neck dissection, offers no
therapeutic advantage over a less-invasive positive core biopsy, as
the patient needs the same dose of radiation.ADVANCED PATHOLOGICAL AND
MOLECULAR DIAGNOSIS FOR
IDENTIFYING PRIMARY SITES
After reviewing imaging, and before endoscopic procedures, our
next step should be more detailed evaluation of neck pathology.
Twenty years ago, the first reports strongly associating a new, less
aggressive variant of OPC with human papilloma virus (HPV)
infection were published (57). Since then, as smoking rates
decreased, HPV-related OPC, characterized by the presence of
high-risk HPV deoxyribonucleic acid (DNA) detected by ISH
and/or real time reverse transcription polymerase chain reaction
(RT-PCR), has increased in incidence relative to the tobacco-
associated form of OPC which is less restricted to the
oropharyngeal subsite. IHC for p16 serves as a surrogate
marker for HPV-related cancer, but can yield false positive
results, and should be confirmed by HPV detection when we
encounter tumors that do not have either the classic basaloid-like
histology or the typical anatomic location in the lingual or
palatine tonsils. Histologically, HPV-related cancers tend to be
exophytic and basaloid in appearance while p16-negative cancers
are frequently infiltrative and are often associated with P53
mutations. There is a heterogeneity of phenotypes within the
p16-negative group, and we will likely refine our understanding
regarding the different presentations of p16-negative cancers as
research progresses in coming years (36, 38, 57, 60). Cancers
outside of Waldeyer’s ring, including oral cavity, larynx and
hypopharynx, are usually p16-negative. According to the
guidelines of the College of American Pathologists, if a
squamous cell carcinoma is p16-positive without the typical
basaloid-like histology or in an anatomic location other than
palatine or lingual tonsil, HPV DNA detection with ISH or RT-
PCR are required to categorize the patient as HPV related
head and neck cancer. In addition, if working with a
cytological sample on a suspected HPV-related cancer, HPV
DNA detection with ISH or RT-PCR must be performed, as false
negative p16 results may be encountered frequently in
cytological specimens (36, 57, 60).
In North America and Western Europe in recent years the
majority of oropharyngeal cancers are HPV-related (70%) and the
incidence of oropharyngeal cancer has increased significantly. The
percentage of other (non-OPC) anatomic subsites that are HPVFrontiers in Oncology | www.frontiersin.org 6related are much smaller and may not carry the same implications
of improved prognosis (38, 61–64).
The diagnosis of an HPV related tumor may be suspected
based on the IHC, the presence of cystic metastases, or the
identification of basaloid cytology or histology, and IHC stains,
particularly for p16. Once this diagnosis is suspected or proven,
it immediately directs the head and neck surgeon toward the
oropharynx at the time of either office examination or
direct laryngoscopy.
The presence of p16-negative cancer in the node on the other
hand, will lead the head and neck surgeon to consider the entire
upper aerodigestive tract at risk. The lymphoid tissue of
Waldeyer’s ring, because it is a site of frequent anatomic
irregularity, remains a site to be sampled, but the head and
neck surgeon will also give extra attention to the larynx
(especially to the supraglottis), nasal cavity, oral cavity (with
special attention to gingiva and oral tongue), hypopharynx, and
cervical esophagus.
While less frequently tested in Europe and North America, in
the case of clinical suspicion of nasopharyngeal origin or
nasopharyngeal-type histology, or inability to find a primary
tumor after panendoscopy, testing for EBV in the neck specimen
is an option (65, 66). Luo et al. looked at the distribution of
located primary sites in EBV positive NCUP, and anatomic
distribution of adenopathy in 269 patients. The distribution of
primary sites included nasopharynx (51.7%), salivary gland
(24.5%), lung (7.8%), oropharynx (3.3%), nasal cavity/
maxillary (3.3%), oral cavity (2.2%), orbit (1.1%), and liver
(0.4%). The rare EBV positive primary lung and liver cancers
that metastasized to the neck, always presented in level IV. Level
V metastases were infrequent from sources other than
nasopharynx (67).
In Southern China, the Middle East and North Africa, EBV
testing is more important than HPV. The location of adenopathy
in the posterior triangle or retropharyngeal nodes might be a clue
in such a situation, but solitary level II nodes can occur, as level II
nodes are actually the second most frequent site (70%) from a
nasopharyngeal primary after retropharyngeal nodes (67, 68).
Testing for EBV involves in-situ hybridization for EBV encoding
region (EBER), a test which has been well validated (65–68).
If a cancer in the neck is so poorly differentiated that the
pathologist is not able to assign squamous origin using a
cytokeratin stain, a broader panel of immunohistochemical
stains becomes important to differentiate squamous cell
carcinoma from lymphoma, adenocarcinoma (thyroid or other),
melanoma, neuroendocrine carcinoma, medullary thyroid cancer,
salivary histologies, etc. Various immunohistochemical markers
such as thyroglobulin, calcitonin, thyroid transcription factor-1
(TTF), Paired-box gene 8 (PAX8), S100 protein, human
melanoma black 45 (HMB 45) can be used (69). Extremely
poorly differentiated lymphomas can express some keratin and
lead to initial misdiagnosis, and flow cytometry and IHC panels
must be directed toward their exclusion. Flow cytometry and IHC
for CD20 and PAX-5, among other B cell markers, can be very
helpful, along with heavy chain gene rearrangement by RT-PCR to
demonstrate clonality (70).November 2020 | Volume 10 | Article 593164
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carcinoma is frequent, diagnostic evaluation of metastatic
carcinoma in lymph nodes of levels I to V, can be difficult.
Even with a history of skin cancer, patients will have to undergo
endoscopic evaluations and biopsies to rule out an upper
aerodigestive tract primary. Furthermore, cutaneous squamous
cell carcinoma can frequently be p16 positive, without any
implications regarding viral etiology or prognosis, further
confusing the picture (71, 72).
Once histopathological tissue is available from the lymph
nodes, new clinically available technologies for “Next Generation
Sequencing” (NGS), i.e. genetic profiling of (DNA) sequences,
can be obtained, and can produce gene profiles associated
with ultraviolet light damage which are more consistent with
skin cancer, or conversely, profiles consistent with upper
aerodigestive tract cancer (73). This knowledge may affect
decisions regarding irradiation of the upper aerodigestive tract
or the contralateral side of the neck postoperatively. As time
progresses NGS will probably settle many additional diagnostic
questions where histology and immunohistochemistry fall short.
Ultimately sequences for HPV-related mutations, EBV-related
mutations, thyroid cancer associated molecular profiles, etc.
could all prove useful (73).
The different DNA sequences encountered in skin cancer
versus upper aerodigestive tract cancer is only one example of
molecular profiling of tumors in order to identify their origin.
These technologies have been extensively used in the development
of “liquid biopsies”, evaluating circulating cancer cells (CTCs) and
cell-free DNA (ctDNA) in a blood sample, which are well-
described for widespread systemic cancer metastases with
unknown primary (CUP), and can involve not only gene
profiling but also gene microarrays (a different genetic
sequencing technology from NGS), and microRNA and DNA
methylation analysis (41, 74–77). Molecular signatures produced
through these technologies can predict the probable primary site
throughout the body with accuracies of 80-95% (74, 77). Whether
these technologies could be further developed to distinguish
between closely related primary sites within the head and neck
for NCUP remains to be determined.ENDOSCOPIC PROCEDURES:
PANENDOSCOPY, NARROW BAND
IMAGING, TRANSORAL ROBOTIC
SURGERY, AND TRANSORAL LASER
MICROSURGERY
In NCUP of levels I, II, III, and VA of the neck, the next step in
the traditional algorithm is the panendoscopy or “triple
endoscopy”, including direct laryngoscopy, rigid or flexible
bronchoscopy, and rigid or flexible esophagoscopy (78). Due to
the exceedingly low incidence of clinically occult primary in the
lung or esophagus with a metastatic node in the neck, many
centers have now abandoned the practice of bronchoscopy and
esophagoscopy in the search of the unknown primary.Frontiers in Oncology | www.frontiersin.org 7Bronchoscopy and esophagoscopy as endoscopic screening for
second primaries, not causative of the neck mass, also remains
controversial, but has its advocates (79–83). On the other hand
direct laryngoscopy and careful endoscopy of the nasopharynx is
clearly warranted. Examination under anesthesia is far superior
to the office examination at identifying a primary tumor, because
of relaxation of the pharyngeal musculature and ability to palpate
base of tongue, tonsils and nasopharynx. Any firm nodularity, or
bleeding on palpation requires biopsy of these suspicious areas
(79, 84, 85).
The literature prior to the era of HPV-related cancer showed
increased survival associated with the initial identification of the
primary tumor in patients with NCUP (86–88). However more
recent publications have not been able to show statistically
improved survival rates, although other benefits occur with
identification of primary tumors, such as precision in planning
radiation ports (89).
Nonetheless, it is logical to do all we can to identify a primary
site. This is tantamount to establishing the correct diagnosis, as
NCUP is a “wastebasket category” that will potentially include
cutaneous, hypopharyngeal, nasopharyngeal, oral cavity,
laryngeal, and oropharyngeal cancers, all of which have
different biological behaviors and would benefit from different
treatment algorithms.
Beyond panendoscopy and biopsy of visible and palpable
lesions, the first attempt to more extensively sample the upper
aerodigestive tract, was the practice of performing random
biopsies of the nasopharynx, oropharynx, hypopharynx and
tongue base in the absence of abnormal endoscopic findings.
These were considered standard for many years and could
fortuitously yield unexpected positive results in rare cases. The
yield on such biopsies however was very low, and this practice
has largely been abandoned (90). Such random biopsies are no
longer included in the NCCN Guidelines, and where
tonsillectomy and lingual tonsil biopsies are advised as well as
directed biopsies based on endoscopic findings (9).
The obvious limitations of random biopsies led to the
development of technologies designed to help the head and neck
surgeon identify the proper site to biopsy in order to find a
primary tumor that is imperceptible to the eye. The most obvious
first step is carefully looking at all of the mucosa under
microscopic magnification and searching for areas of subtle
leukoplakia, erythroplasia, roughness, or minimal papillomatous
tissue. More powerful optical enhancement technologies have also
been developed. The most proven of these is narrow band imaging
(NBI), which works by restricting light to two spectral
wavelengths, the blue (400-430nm) and green (525-555 nm).
The blue enhances capillaries and green enhances deeper blood
vessels, and the overall effect makes lesions, whether dysplastic or
early malignancy, easier to detect. It can be used during office
fiberoptic nasopharyngoscopy or at the time of panendoscopy
under anesthesia (91).
In combination with white light imaging, NBI has high
sensitivity and negative predictive values. In one systematic
review, the sensitivity and specificity for NBI in NCUP setting
was 74% (range, 58% to 87%) and 86% (range, 76% to 93%),November 2020 | Volume 10 | Article 593164
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the curve of >0.9, suggesting that NBI is an excellent tool for
localizing the mucosal primary in patients with NCUP (92). A
more recent systematic review confirmed this accuracy, with a
pooled sensitivity and specificity in patients with NCUP of 0.83
(99% CI, 0.54–0.95) and 0.88 (99% CI, 0.55–0.97), respectively.
The pooled diagnostic odds ratio (DOR) was 82.15 (99% CI,
7.06–955) and the overall detection rate of NBI was 0.35 (99% CI,
0.18–0.53), which allowed localization of the primary tumor in
61 out of 169 patients (93). These studies suggest that NBI could
have considerable diagnostic value in NCUP, increasing the
likelihood of finding the mucosal lesion that is responsible for
regional metastatic spread to the neck. Therefore, this non-
invasive adjunct to the conventional fiberoptic examination
should be considered for routine use in these patients.
There has also been a movement toward removing normal
appearing tonsillar tissue as a means of achieving a diagnosis
of a primary tumor. First unilateral and then bilateral palatine
tonsillectomy became standard for NCUP in the 1980’s and
1990’s, which was proven to increase the identification
of primary tumor sites in a significant percentage of patients,
while adding little additional long-term morbidity (89, 94,
95). Interestingly, approximately 10% of tonsillar primaries
are found in the tonsil contralateral to the lymphatic
metastases (96).
Unlike the palatine tonsils, lingual tonsil removal was not a
common operation traditionally. The lingual tonsils are not
frequently chronically infected, are not directly accessible
transorally, require access at a 30-degree upward angle, and are
less encapsulated than the palatine tonsils. Lingual tonsillectomy
was not widely performed for non-neoplastic indications. As the
surgical robot became available, different medical specialties
started to incorporate its use. In head and neck surgery the da
Vinci surgical robot, manufactured by the Intuitive Surgical, was
first applied to the transoral resection of cancers of the
oropharynx (TORS) (97).
Mehta et al. in 2013 first reported endoscopic bilateral lingual
tonsillectomy with the assistance of the surgical robot in NCUP.
They performed this procedure on 10 patients who had already
had direct laryngoscopy, directed or random biopsies, and
palatine tonsillectomies. Primary tumors were identified in the
lingual tonsil tissue in 9 of the 10 with a mean diameter of 0.9
centimeters (98). In the same year Nagel et al. published the
results of 36 lingual tonsillectomies in NCUP using laser
microsurgery with identification of the primary tumor in
86% (99).
Multiple other authors have confirmed the effectiveness of
robotic lingual tonsillectomy at locating primary tumors (90,
98, 100). Ryan et al. (89)reviewed the records of 110 patients
diagnosed with NCUP. Direct laryngoscopy identified a primary
tumor in 31% of patients. Forty-seven patients underwent
palatine tonsillectomy, which identified 17 primaries (36%),
yielding a cumulative primary tumor identification of 51/110
(46%). Finally, 14 patients underwent TORS lingual
tonsillectomy, which identified eight primaries (57%), resulting
in a cumulative identification of 59/110 (53%). The detection rateFrontiers in Oncology | www.frontiersin.org 8increased from 44% to 66% after the addit ion of
lingual tonsillectomy.
The use of transoral laser microsurgery (TLM) to achieve the
same end, using a combination of microscope and telescopes, has
also been described by multiple other authors (101–103).Regardless
of the technique chosen, palatine and lingual tonsillectomy will
locate a primary tumor in approximately 70% of patients with
NCUP who have completely negative office evaluations and
imaging, including PET-CT, particularly in the HPV+ setting (102).
Technically, it is important to preserve uninvolved non-
lymphoid mucosa between the tonsillar tissue and avoid a
circumferential wound, in order to prevent oropharyngeal
stenosis. Thus, patients have done well functionally as long as
an area, often in the contralateral lingual tonsil and glosso-
pharyngeal sulcus, is sampled but not removed en bloc. The
surgical robot, is a useful instrument which allows the surgeon
to work in a tight space controlling the small “hands” of the
instrument by remote control with cautery, graspers, etc. When
the robot is not available, we have found it helpful to work two-
handed with the FK retractor, and an assistant holding a 30-degree
telescope to provide the angle needed to visualize the lingual tonsil
well, and this can be complementary to the microscope.
Although no literature discusses this formally, if a patient
with NCUP has a significant adenoid pad, unusual in the adult
age group, adenoidectomy should be considered under the same
logic that leads us to do palatine and lingual tonsillectomies. It
should also be mentioned that, although the likelihood of an
oropharyngeal primary is higher in HPV positive patients, the
algorithm for management of the primary in the neck, in terms
of imaging, endoscopies, and removal of lymphoid tissue, as
illustrated in Figure 1, is similar for all squamous cell carcinomas
in the cervical lymphatics, regardless of HPV status.
The combination of wounds in both tonsils, across the tongue
base, and in the nasopharynx, adds additional risk of bleeding
and leads to odynophagia in the short term. Since the cancer is
more likely to be ipsilateral than contralateral, it is unclear when
and how to perform all of these staging procedures, allowing for
the maximal staging benefit while minimizing risk and
discomfort. We can start with panendoscopy, and biopsy any
area that stands out as irregular or that bleeds easily. The next
step would be to perform palatine tonsillectomies, and obtain
frozen section, followed by ipsilateral lingual tonsillectomy and
frozen section, and then contralateral lingual tonsillectomy. If a
primary has not been identified, we can now consider sampling
any available lymphoid tissue in the nasopharynx. With such an
approach, the majority of primary tumors should be identified. It
needs to be acknowledged that frozen section is not as sensitive
as definitive histology and that the primary may still not be seen
until final pathology.
To reduce or avoid the use of frozen section, the procedure
can, alternatively, be divided, with panendoscopy and palatine
tonsillectomy at one intervention and lingual tonsillectomy at a
second one. This approach produces throat pain and risk of
bleeding for the patients twice rather than once. Some propose it
may reduce the risk of oropharyngeal stenosis. The risk-benefit
ratio of performing palatine tonsillectomy at the same time asNovember 2020 | Volume 10 | Article 593164
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formally studied in a randomized trial.UNDISCOVERED PRIMARIES REMAINING
AFTER EXTENSIVE ENDOSCOPIES AND
ENDOSCOPIC RESECTIONS: ARE THEY
UNIQUE?
One might ask where the primary tumor is hidden in a patient who
has undergone careful endoscopy with optical enhancement, and
has had all of their pharyngeal lymphatic tissue removed. The
incidence of subsequent development of clinically evident primary
tumors in patients who receive neck dissection for NCUP and are
observed without radiation is relatively low, between 10 and 30% in
an era where palatine tonsillectomies and lingual tonsillectomies
were not done (104, 105).Yet in theory, since no treatment was
directed to the mucosal primary, a clinically progressive throat
cancer should have become evident over time in 100% of those
patients. This has led some to propose that regression of the primary
tumor was occurring in occasional cases.
Tumor regression can infrequently occur for other tumor
types that are known to be very immune sensitive, such as
cutaneous Merkel cell carcinoma and melanoma, and there are
actually hundreds of case reports of regressed cancers, including
some squamous cell carcinomas (106, 107). However, the
experience in patients with clinically evident squamous cell
carcinoma would indicate that once there is a measurable
primary cancer, it is extremely rare for this to regress.
On the other hand, Califano et al. in 1999 performed a very
interesting study that may provide some insight. Their group
performed microsatellite analysis on metastatic adenopathy and
benign surveillance biopsies from 18 patients with NCUP. In 10
of the 18 patients, at least one benign biopsy specimen from sites
at risk for occult primary tumor demonstrated a pattern of
genetic alterations identical to that present in the lymph node
metastases. Thus, while the tissue was phenotypically benign, it
was “genetically malignant” (108).
Two of their patients subsequently grew cancers in the same
mucosal region. They proposed that phenotypically normal
mucosa, perhaps with foci of phenotypic cancer so small they
could not get picked up on biopsy, had sufficient mutations to
permit those cells tometastasize to lymph nodes, but not to behave
in a locally proliferative or invasive manner at the primary site. He
proposed that mucosal biopsies could be evaluated genetically and
that areas with genetic signatures that matched the cancer could be
targeted for radiation. Obviously, this concept would need to be
validated, but clearly this would represent a much more
sophisticated level of evaluation, and merits investigation (108).TREATMENT
Treatment of NCUP is based on the primary tumor site, if
identified, and on the N stage of the neck disease, as it would beFrontiers in Oncology | www.frontiersin.org 9for any other head and neck cancer. The nuances of navigating
treatment in the small group of patients in whom the primary
tumor remains unknown after an extensive search were covered
in great detail by Strojan et al. in 2013 who dedicated an entire
review in their two part publication to this subject (2). Since that
publication 7 years ago the principal change that has occurred in
North America and Europe is the routine testing of all OPCs, and
sometimes other anatomic subsites as well, for p16 IHC, and
sometimes for HPV DNA or mRNA ISH or RT-PCR, in order to
categorize tumors as HPV-related or not.
The first step in planning treatment always involves a
hypothesis regarding the probable occult primary site. The
first clue used is the distribution of the adenopathy by
anatomic levels. One would expect this distribution to vary
by geographic region depending on the prevalence of cutaneous
malignancy, which varies greatly by ethnicity and skin type, as
well as by the prevalence of EBV and HPV related upper
aerodigestive tract cancers. In general, adenopathy in NCUP
is most commonly in level II, which suggests primary sites in
the oropharynx, hypopharynx, or supraglottic larynx, although
isolated level II metastases can also occur with oral cavity
cancer and nasopharyngeal cancer. NCUP with isolated level
I (submandibular and submental) adenopathy is less frequent,
and points to oral cavity and skin primary sites. As part of a
study targeting level I, Ozer et al. in 2010 reported that level I
adenopathy occurred in 2 (11.1%) of 18 patients with NCUP
(109). The rest of their level I nodes were distributed among
known oral cavity (19.1%), oropharynx (9.8%), and larynx
(4.4%) cases, and none were observed with hypopharyngeal
cancer (0%). Oral cavity cancer in particular went to level I in
55% followed by level II (20%) and level III (19%), and level IV
and V in only 3% each (and generally the latter were in the
presence of extensive adenopathy in levels I, II and III). OPC
patients only had level I adenopathy in the presence of
extensive adenopathy in other levels. One might anticipate a
lower incidence of level I NCUP in regions that have lower rates
of cutaneous malignancy (110).
Similarly, the presence of level V adenopathy will lead to
consideration of primary tumors of the nasopharynx or posterior
scalp (68, 111). Given the predominance of EBV-negative NCUP
in levels II and III, our discussion regarding treatment will be
focused on this group.
It is well documented that the rate of appearance of a
clinically evident primary tumor in the upper aerodigestive
tract during follow-up surveillance after treatment of NCUP is
low (112, 113). With neck dissection and close observation, while
primary emergence still does not occur in the vast majority of
patients, there is a somewhat higher rate of development of
clinically evident primary tumors in the upper aerodigestive tract
compared to patients who receive radiation to the upper
aerodigestive tract. These numbers range widely, possibly
depending on factors such as the completeness of the
endoscopic evaluations to search for a primary, the prevalence
of EBV and HPV related cancers in the region, and the
prevalence of cutaneous malignancy (112, 113). Primary site
emergence rates can range from 2% to 50% with most recentNovember 2020 | Volume 10 | Article 593164
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data are hard to interpret as it is difficult to know, for each center,
how aggressive the initial search for a primary tumor was. For
centers reporting lower rates, these approximate the rate of
expected development of new primary tumors in patients
cured from known primary tumor, and there is a question as
to whether we are actually just detecting new primary tumors in
the at-risk mucosal field (2).
Interestingly recent reports regarding unilateral neck
radiation without mucosal fields have reported extremely low
primary emergence. Takes et al. for a population that was
primarily HPV negative, reported equivalent survival and no
primary site emergence after unilateral irradiation to the
neck in 42 patients with low volume unilateral NCUP (115).
Others have reported similar results in HPV negative
populations in recent years (114). Strojan et al. found no
significant difference when they compared the risk of
metachronous second primary tumors in patients with known
primaries, and the risk of appearance of a mucosal primary in
NCUP patients who were diagnosed during the same time span
and were postoperatively irradiated either with involved-field
or extended-field technique (116). Certainly, with HPV-related
cancer that has undergone tonsillectomies and partial lingual
tonsillectomy, it appears even less likely for a primary to emerge
in a delayed fashion (117).
The reasons that primary emergence appears to be much less
frequent in this setting is unclear, but we can conjecture that with
primary neck radiation we are likely delivering enough dose to
the at-risk mucosal sites, particularly the ipsilateral tonsil and
tongue base, to achieve occult primary control (118). This seems
unlikely to completely explain the reduced rate of primary
emergence, as certainly some contralateral and out-of-field
primary sites would be expected to emerge. A rising incidence
of squamous cell carcinoma of the skin and more rigorous
pretreatment evaluation of pharyngolaryngeal mucosal sites
may also be factors (110, 111).
In 2018 the American Joint Committee on Cancer (AJCC)
updated its staging system for HPV-related OPCs, (119) which
makes discussion based on stage more difficult. However, for
low volumes of neck disease, as advocated by Strojan et al., and
others (2, 112, 120), it is clear that one option is radiation
alone, preferably after core biopsy for histology. After unilateral
neck irradiation of nodal disease, without attempting to
comprehensively treat mucosa aggressively, but rather selectively
treating highest risk areas, cure rates of 92% for early disease are
obtained (2, 105). Treatment volumes are targeted based on tumor
volume, anatomic levels of neck involvement, and HPV or EBV
status. Radiation typically involves intensity modulated radiation
therapy (IMRT) or 3D conformal radiation to reduce dose to
critical structures with doses of 66 to 70 Gy, 2–2.2 Gy per fraction,
on weekdays over approximately 6 to 7 weeks. For lower risk
anatomic areas lower doses are used between 44 and 63 Gy (9).
Another approach is to treat as one would for a T1 oropharyngeal
SCC, because most of the NCUP are likely located in the tonsil and
tongue base. This involves irradiation to the oropharynx,Frontiers in Oncology | www.frontiersin.org 10retropharyngeal nodes, and both sides of the neck. The main
disadvantage of ipsilateral neck irradiation alone is the risk of
failing in the base of tongue and contralateral neck.
Though side effects are less with unilateral neck irradiation
that is not specifically directed at mucosal sites, xerostomia,
mucosal atrophy, poor healing capacity in the radiated field,
osteoradionecrosis, dysphagia and other dysfunction related
to soft tissue fibrosis, and secondary malignancies, are
all known late sequelae of radiation although less common
and of lower intensity when using modern radiotherapy
techniques (121).
A second approach for patients remaining in the NCUP
category with low volume neck disease would be to start with
neck dissection, which can be unilateral or bilateral (9, 104, 112,
120). This approach, which is the preferred approach under the
NCCN guidelines (9) is advocated based on avoiding or reducing
radiation, thereby lessening the risk of late toxicities, and
obtaining more staging information. Neck dissection has its
own morbidities, of which the most notable would be the risk
of shoulder dysfunction related to manipulation of cranial nerve
XI, which is usually transient.
If the patient and physician opt for neck dissection, and the
final pathology report indicates a single involved lymph node, less
than 3 centimeters in dimension, with low risk histopathological
features (i.e. no extranodal extension, adequate number of
dissected nodes available for histopatologic examination),
current guidelines suggest that the patient can be closely
observed with serial examination of the upper aerodigestive tract
and serial fiberoptic office naso-pharyngo-laryngoscopy (9, 112).
We expect a small percentage of these patients to reveal primary
sites on long term follow-up, but no high level randomized data
indicates the risk level involved in this choice. In some centers,
such patients will be offered a postoperative dose of radiation, with
or without a moderate radiation treatment to the highest risk
mucosal surfaces, which can be restricted to the oropharynx for
the HPV positive patients. This latter approach would still have
significant reductions in dose and volume relative to primary
radiation without neck dissection and would be standard for
patients with multiple nodes or nodes larger than 3 centimeters.
Multiple trials are ongoing studying HPV related cancers, and
further de-escalations in treatment are being considered.
Postoperative radiation in low to intermediate risk patients can
involve doses of 44 to 63 Gy, with higher doses for areas with high
risk pathological features. Extranodal extension, in particular,
leads to an indication for adding chemotherapy to post
operative radiotherapy (2, 9).
For advanced disease in the neck, surgery followed by
radiation or combination of concurrent chemotherapy and
radiation are the major options. For the HPV-related cancer,
the latter will likely be recommended. For HPV negative cancer
in an advanced state, if a reasonable resection can be devised to
precede radiation, this may be preferred, but chemoradiation
protocols that seek to avoid the dysfunction associated with
radical neck dissection or extended radical neck dissection can
also be offered. Strojan et al. (2) recommended surgery followedNovember 2020 | Volume 10 | Article 593164
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dissection in case of residual disease, and this was the algorithm
typically applied to HPV-negative cancers, with documented
improvements in survival when surgery was included in the
initial treatment plan (2, 122). However, planned neck dissection
in all patients, is no longer recommended. Salvage neck
dissection is performed in patients with documented persistent
neck disease, or residual adenopathy highly suspicious for
viable cancer.
With HPV-related cancer, chemoradiation alone leads to high
locoregional control rates, and the modern algorithm would be
to treat advanced disease with chemoradiation protocols, usually
including intravenous cisplatin in patients who can tolerate this
agent and perform a PET CT at 3 to 6 months after treatment,
followed by close clinical observation if deemed negative (9).
Radiation dose is generally 70 Gy, 2 Gy per fraction to the grossly
involved neck, and 50-60 Gy to mucosal sites at risk for
harboring an occult primary, with increased doses of 60-66 Gy
directed at highest risk sites (9) (Figure 2).
If a midline primary site of origin, i.e. base of tongue, cannot
be ruled out, most radiation oncologists will prefer to treat neck
bilaterally, as coming back to radiate later is usually difficult.
Bilateral neck irradiation yielded non-significant improvements
in mucosal and cervical disease control, albeit with significantly
increased morbidity (123).
The functional differences between avoiding radiation to the
mucosa, using limited fields to the oropharynx, and full mucosal
irradiation to the nasopharynx, oropharynx, hypopharynx, and
larynx, are significant. The latter, which historically represented
the traditional treatment for NCUP is now occasionally used for
HPV negative cases, mainly in patients with uncommon
presentations such as level IV disease without positive nodes in
level II and III. Many radiation oncologists prefer to treat the
oropharynx, retropharyngeal nodes, and both sides of the neck.
Enlarging the target volume to tightly include the nasopharynx
may be considered and does not significantly increase morbidity.Frontiers in Oncology | www.frontiersin.org 11Routine inclusion of the larynx and hypopharynx is unlikely to
encompass the NCUP and, thus, it does not compromise
outcome but significantly increases morbidity and should be
avoided if possible (124).CONCLUSIONS
Modern management of metastatic neck cancer with an
unknown primary site requires proper recognition of the
typical clinical presentation, and avoidance of diagnostic
pitfalls that can lead to inappropriate interventions. Patients
should be imaged with CT or MRI, and PET-CT, and receive a
complete examination of the mucosal surfaces of the upper
aerodigestive tract, preferably enhanced by the use of NBI.
Ultrasound guided fine needle aspiration should be used for
initial tissue diagnosis, but eventually histologic biopsy should be
obtained, preferably from the occult primary site. HPV status,
other immunohistochemical stains, and even next generation
gene sequencing can guide us to probable primary sites.
Tonsillectomy and lingual tonsillectomy may be indicated to
identify a possible primary site.
Decisions regarding therapy are based on the primary tumor
site, if identified, the stage of the neck disease, and the HPV/EBV
status of the tumor. Neck dissection can be used to reduce
radiation dosage in these patients and acquire increased
histopathological risk stratification. We may be at the limit of
what can be achieved by surgical technologies in terms of
maximizing the rate of identification of primary tumors. Gene
microarrays, and other molecular technologies, applied to at risk
mucosal sites, may be the next step in identifying primary sites to
target for treatment.
Both the diagnostic and therapeutic guidelines regarding
management of NCUP continue to vary between medical
centers. Core biopsy, lingual tonsillectomy, surgical treatment,
primary radiation, surgery followed by radiation, chemoradiation,FIGURE 2 | 73-year-old man with an human papilloma virus (HPV) 16 positive squamous cell carcinoma from an unknown primary site with bilateral positive level 2
lymph nodes. The patient was treated with deintensified intensity modulated radiotherapy (IMRT) to 60 Gy in 30 once daily fractions to the oropharynx and bilateral
positive nodes and 54 Gy in 30 fractions to the retropharyngeal nodes on the side with bulkier neck disease and levels 3 and 4 bilaterally. Concomitant weekly
cisplatin 30 mg/M2 was administered. The patient tolerated treatment well and has remained disease free for 4.5 years without complications.November 2020 | Volume 10 | Article 593164
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at different frequencies by different groups, even sometimes within
the same geographic region (125).
Since NCUP, though more frequent in the HPV era, remains
an uncommon diagnosis, it is difficult to perform large trials that
lead to consensus. We hope to support the goal of achieving a
consensus regarding the proper evaluation, subclassification, and
treatment of these patients.AUTHOR CONTRIBUTIONS
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